// App-Quantinova.ai

OP0227 : SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY

Researchers

Presenter

  • I. Mcinnes

Principal Investigators

  • F. Behrens

  • P. J. Mease

  • A. Kavanaugh

  • C. T. Ritchlin

  • P. Nash

  • J. Gratacos-Masmitja

  • P. Goupille

  • T. Korotaeva

  • A. B. Gottlieb

  • R. Martin

  • K. Ding

  • P. Pellet

  • S. Mpofu

  • L. Pricop

Medical Centers

  • University of Glasgow, Glasgow, United Kingdom

  • Rheumatology University Hospital, Frankfurt, Germany

  • Swedish Medical Centre, Seattle, United States of America

  • UCSD, La Jolla, United States of America

  • University of Rochester Medical Center, Rochester, United States of America

  • Griffith University, Nathan, Australia.

  • University Hospital Parc Tauli Sabadell, Barcelona, Spain

  • University Hospital of Tours, Tours, France

  • Research Institute of Rheumatology n.a. V.A. Nasonova, Moscow, Russian Federation

  • Icahn School of Medicine at Mount Sinai Hospital - New York - United States of America

  • Novartis Pharmaceuticals Corporation East Hanover NJ United States

  • Novartis AG, Basel, Switzerland

Locations

  • United Kingdom

  • Germany

  • United States

  • Australia

  • Spain

  • France

  • Russia

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Superiority

  • Active Comparator

Phase

  • III

Study Id's

  • NCT02745080

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved